The Evolving Treatment Landscape in Hepatocellular Carcinoma: New Agents and the Role of Biomarkers in First-Line Treatment

0.50 CME
30 MINS
$0 FEE
SAVE
hep

Overview

Provider Statement

Provided by Integrity Continuing Education, Inc.


Support Statement

Supported by educational grants from Eisai and Merck & Co., Inc.


Target Audience

Medical oncologists, interventional radiologists, radiologists, gastroenterologists, hepatologists, and oncology advanced practice providers, as well as nurses and other professionals involved in the management of patients with HCC. 


Learning Objectives

Upon completion of this educational activity, participants will be able to: 

  • Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in first-line HCC treatment settings
  • Implement strategies to identify, monitor, and manage treatment-related AEs

Faculty

eileen
Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head Hepatopancreaticobiliary & Neuroendocrine Cancers
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York


Reviewer

Michelle R. Rizzo, ELS 


Accreditation

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.


Credit Designation

Integrity Continuing Education, Inc. designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


How to Participate in this Activity and Obtain CME Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 10, 2020 through February 10, 2021, participants must: 

  • Read the learning objectives and faculty disclosures 
  • Complete the pretest
  • Study the educational activity 
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.


Disclosures

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty reports the following relationship(s)

Eileen M. O’Reilly, MD
Consulting Fees: 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, Beigene, Bioline, BMS, Boston Scientifc, Bridgebio, Carsgen, Celgene, Casi, Cipla, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Flatiron, Genoscience, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Jansen, Klus, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Novella, Onxeo, PCI Biotech, Pfizer, Pieris, QED, Redhill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira, Twoxar, Vicus, Yakult, Yiviva
Contracted Research: ActaBiologica, Agios, Array, Astra Zeneca, Bayer, Beigene, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, Mabvax, Novartis, OncoQuest, Polaris Puma, QED, Roche

Reviewer reports the following relationship(s)

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 


Unlabeled and Investigational Usage

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., Eisai, and Merck Sharp & Dohme Corp. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.